U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06874335) titled 'A Phase 1 Study of BHV-1530 (AMB302) in Advanced Solid Tumors' on March 04.
Brief Summary: This is a Phase 1, first in human (FIH), open-label, multicenter study of BHV-1530 in adult participants with advanced or metastatic solid tumors.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Solid Tumor
Intervention:
DRUG: BHV-1530
BHV-1530 will be administered as an IV infusion on Day 1 of each 21-day cycle
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Biohaven Therapeutics Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....